|AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in pancreatic cancer|
|By: GlobenewsWire - 23 Feb 2021||Back to overview list
NEW INDEPENDENT PUBLICATION IN THE PEER-REVIEWED SCIENTIFIC REVIEW CELLS CONFIRMS THE ROLE OF MASITINIB AS A POTENTIAL THERAPY IN PANCREATIC CANCER
IDENTIFICATION OF TWO TISSUE BIOMARKERS THAT COULD POTENTIALLY SERVE AS PREDICTIVE BIOMARKERS OF RESPONSE FOR MASITINIB TREATMENT
Paris, 23 February 2021, 8am CET
AB Science SA (NYSE Euronext - FR0010557264 - AB) today announced the publication of a peer-reviewed research article in which the authors conclude that inhibition of mast cells with masitinib could represent a novel antiangiogenetic approach in pancreatic cancer (antiangiogenic therapies reduce the growth of new blood vessels needed by tumors to grow and metastasize). The article, entitled ‘Mast Cells Positive for c?Kit Receptor and Tryptase Correlate with Angiogenesis in Cancerous and Adjacent Normal Pancreatic Tissue’,  is freely accessible online from the Cells journal site https://www.mdpi.com/2073-4409/10/2/444
This study examined mast cell activity through immunohistochemistry and image analysis, in a series of non-metastatic pancreatic cancer patients. Results showed that:
This research supports results from the confirmatory phase 3 study, AB12005, that evaluated masitinib at 6.0 mg/kg/day in combination with gemcitabine as a first-line treatment of unresectable locally advanced or metastatic pancreatic cancer patients with pain; pain being hypothesized to be a marker of mast cell activation.
Andrew Hendifar, MD, MPH, Head of Gastrointestinal Oncology at Cedars-Sinai Medical Center in Los Angeles said: “This research provides new and robust evidence confirming the relevance of targeting mast cells in pancreatic cancer. Furthermore, the identified tissue biomarkers could potentially be used as an alternative or additional marker to pain when initiating masitinib treatment in patients with locally advanced pancreatic cancer.”
As a reminder , study AB12005 met its primary objective to demonstrate increase in survival in pancreatic cancer patients with pain. In the population with unresectable locally advanced tumors with pain, the masitinib treatment-arm showed a significant improvement in overall survival (OS) relative to the control arm. The between group difference in median OS was 1.8 months (p=0.007) in favor of masitinib (13.0 months in masitinib arm versus 11.2 months in control group), with a 0.46 hazard ratio (HR) of death, which represents a reduction in risk of death of 54% for masitinib-treated patients relative to control. Results on the primary endpoint were consistent with secondary analysis in progression free survival (PFS), which measures the time to tumor progression or death (whichever occurs first) from the start of treatment. The between group difference in median PFS was 1.8 months (p=0.039) in favor of masitinib (7.4 months in masitinib arm versus 5.6 months in control group), with a 0.47 hazard ratio representing a reduction in risk of having a progression or death of 53%. The safety of masitinib 6.0 mg/kg/day in combination with gemcitabine compared favorably to that of gemcitabine as a single agent, with fewer adverse event and severe adverse events reported in the masitinib arm as compared with the control arm.
 Ammendola, M.; Curr, G.; Laface, C.; Zuccal, V.; Memeo, R.; Luposella, F.; Laforgia, M.; Zizzo, N.; Zito, A.; Loisi, D.; et al. Mast Cells Positive for c?Kit Receptor and Tryptase Correlate with Angiogenesis in Cancerous and Adjacent Normal Pancreatic Tissue. Cells 2021, 10, 444. https://doi.org/10.3390/cells10020444
 AB Science press release. Dec 04,2020. http://www.ab-science.com/years/2020/
About AB Science
Further information is available on AB Science’s website: www.ab-science.com.
Forward-looking Statements - AB Science
These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents filed by AB Science with the Autorité des Marchés Financiers (AMF), including those listed in the Chapter 4 "Risk Factors" of AB Science reference document filed with the AMF on November 22, 2016, under the number R. 16-078. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.
For additional information, please contact:
Media Relations – USA
+1 646 432 0191
Media Relations – France
+33 (0)1 44 71 00 15
Copyright 2021 GlobenewsWire
|Back to overview list|